Running Title: Average Daily Risk after STEMI

Gennaro Giustino, MD[a,b], Roxana Mehran, MD[a,b], George D. Dangas, MD, PhD[a,b], Ajay J. Kirtane, MD, MSc[b,c], Björn Redfors, MD, PhD,[b] Philippe Genereux, MD[b,d], Sorin J. Brener, MD[b,e], Jayne Prats, PhD[f], Stuart J. Pocock, PhD,[g] Efthymios N. Deliargyris, MD[h], and Gregg W. Stone, MD[b,c]

[a]The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; [b]Cardiovascular Research Foundation, New York, NY, USA; [c]Division of Cardiology, New York-Presbyterian Hospital, Columbia University Medical Center, New York City, NY, USA; [d]Morristown Medical Center, Morristown, NJ; [e]Department of Medicine, New York Methodist Hospital, New York City, NY, USA; [f]The Medicines Company, Parsippany, NY, USA; [g]London School of Hygiene and Tropical Medicine, London, United Kingdom; [h]Science and Strategy Consulting Group, Basking Ridge, NJ, USA

Word count: 4,984

Pharmaceuticals, Medtronic, AUM Cardiovascular, Inc., Beth Israel Deaconess Medical Center; executive committee - Janssen Pharmaceuticals, Osprey Medical Inc.; data safety monitoring board - Watermark Research Partners; consulting - Medscape, The Medicines Company, Boston Scientific, Merck & Company, Cardiovascular Systems, Inc. (CSI); Sanofi USA, LLC, Shanghai BraccoSine Pharmaceutical Corp.; AstraZeneca; equity - Claret Medical Inc., Elixir Medical Corporation. Ajay J. Kirtane: Institutional research grants to Columbia University from Boston Scientific, Medtronic, Abbott Vascular, Abiomed, St. Jude Medical, Vascular Dynamics, and Eli Lilly. Philippe Généreux: Speaker's fee – Abbott Vascular and Edwards Lifescience; consulting fee – Cardiovascular Systems Inc, PiCardia, Soundbite Medical Solutions; institutional research grant – Boston Scientific, Tryton Medical. Stuart J. Pocock: Consultant - Abbott Vascular. Efthymios N. Deliargyris: Shareholder – The Medicines Company. The rest of the authors: None.

Corresponding Author

Gregg W. Stone, MD

Columbia University Medical Center

Cardiovascular Research Foundation

111 East 59th Street, 11th Floor

New York, NY 10022

tel: 646-434-4134

fax: 646-434-4715

e-mail: gs2184@columbia.edu; gstone@crf.org

Abstract

Background: The risk of recurrent ischemic and bleeding events after primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) may not be uniform over time, which may impact the benefit-risk ratio of guideline-recommended antithrombotic therapies in different intervals.

Objectives: We sought to characterize the average daily ischemic rates (ADIR) and average daily bleeding rates (ADBR) within the first year after primary PCI for STEMI.

Methods: Among 3,602 STEMI patients enrolled in the HORIZONS-AMI trial, all ischemic and bleeding events, including recurrent events, were classified according to the timing of their occurrence as acute ($\leq$24 hours after PCI), subacute (day 1 to 30), and late (day 30 to 1 year). Patients were treated with aspirin and clopidogrel for the entire year. ADIR included cardiac death, reinfarction and definite stent thrombosis. ADBR included non-CABG-related TIMI major and minor bleeding. ADIR and ADBR were calculated as the total number of events divided by the number of patient-days of follow-up in each interval assuming a Poisson distribution. Generalized estimating equations were used to test the absolute least square mean differences (LSMD) between ADIR and ADBR.

Results: The ADIR and ADBR both exponentially decreased from the acute to the late periods (p<0.0001). While there were no significant differences in ADIR and ADBR in the acute phase (LSMD: +0.11%; 95% CI: -0.35% to 0.58%; p=0.63), the ADBR was greater than the ADIR in the subacute phase (LSMD: -0.39%; 95% CI: -0.58% to -0.20%; p<0.0001). In the late phase, the ADIR exceeded the ADBR (LSMD: +1.51%; 95% CI: 1.04% to 1.98%; p<0.0001).

Conclusions: After primary PCI, the ADIR and ADBR both markedly decreased over time. While the rates for bleeding exceeded those for ischemia within 30 days, the daily risk of

1 ischemia significantly exceeded the one of bleeding beyond 30 days, supporting the use of

2 intensified platelet inhibition during the first year after STEMI.

3 **Key Words:** STEMI; PCI; Average Daily Rate; Ischemic Events; Bleeding Events.

4

5

1   **Condensed Abstract**

2   We characterized the average daily ischemic rate (ADIR) and average daily bleeding rate

3   (ADBR) within the first year after primary PCI for STEMI. The ADIR and ADBR both

4   exponentially decreased from the acute to the subacute to the late periods (p<0.0001). While the

5   ADBR was greater than the ADIR in the first 30 days (least square mean difference [LSMD]: -

6   0.39%; 95% CI: -0.58% to -0.20%; p<0.0001), the ADIR significantly exceeded the ADBR

7   beyond 30 days (LSMD: +1.51%; 95% CI: 1.04% to 1.98%; p<0.0001), supporting the use of

8   intensified platelet inhibition during the first year after STEMI.

1   **<u>Abbreviation List</u>**

2   ADR = Average daily rate

3

4   ADIR = Average daily ischemic rate

5

6   ADBR = Average daily bleeding rate

7

8   GPI = Glycoprotein IIb/IIIa inhibitor

9

10   MI = Myocardial infarction

11

12   PCI = Percutaneous coronary intervention

13

14   STEMI = ST-segment elevation myocardial infarction

15

16   ST = Stent thrombosis

17

18   UFH = Unfractionated heparin

Patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) are at high risk for ischemic and bleeding events, both of which strongly impact subsequent morbidity and mortality (1-4). The selection of optimal antithrombotic agents in the acute and chronic phases after STEMI, in terms of their potency and duration, requires a careful evaluation of the offsetting risks of ischemia and bleeding (5-7). While the predictors and impact of ischemic and hemorrhagic events after primary PCI in STEMI have been investigated (1,2), their absolute and relative rates over time remain uncertain. In this regard the risk for recurrent ischemic and bleeding events may not be uniform over time, a consideration which may influence the benefit-risk ratio of guideline recommended antithrombotic therapies. For example, since the highest rate of ischemic events occurs in the first few days or weeks after STEMI (8,9), a strategy of potent platelet inhibition might be considered during the first month after patient presentation, if the bleeding risk is not excessive in this period. Thereafter down-titrating to a less potent regimen might offer a favorable balance of ischemic protection vs. bleeding avoidance. Such considerations rely on understanding the relative risks of ischemia and bleeding in different risk periods.

All adverse outcomes (including recurrent events) must be considered for the true burden of ischemic and bleeding complications to be fully appreciated. However, conventional time-to-event analyses censor patients after the first endpoint event is experienced, thereby masking subsequent recurrent adverse events, reducing statistical power and diminishing appreciation for the potential benefit (or harm) of preventative therapies (10). We therefore determined the average daily rate (ADR) of all ischemic and bleeding events in the first year after primary PCI in patients enrolled in the Harmonizing Outcomes with RevascularIZatiON and Stents in Acute

1 Myocardial Infarction (HORIZONS-AMI) trial, to better characterize the total and temporal-

2 related burden of adverse outcomes after STEMI.

3

4 **METHODS**

5 **Study Design and Objectives.** The study design of the HORIZONS-AMI trial has been

6 previously described (11,12). Briefly, HORIZONS-AMI was a multicenter, international, open-

7 label, 2 x 2 factorial randomized controlled trial that enrolled 3,602 patients presenting with

8 STEMI within 12 hours from onset of symptoms. Eligible patients were randomized 1:1 to

9 unfractionated heparin (UFH) plus a glycoprotein IIb/IIIa inhibitor (GPI) versus bivalirudin. A

10 total of 3,202 eligible patients were then randomized again in a 3:1 ratio to either implantation of

11 a paclitaxel-eluting stent or a bare metal stent. Aspirin 324 mg chewed or 500 mg intravenously

12 was given before PCI, and 75 to 81 mg po qd was prescribed indefinitely after discharge. A

13 loading dose of clopidogrel (300 or 600 mg per investigator discretion) was administered pre-

14 PCI, followed by 75 mg po qd for at least 1 year. Clinical follow-up was performed at 30 days, 1

15 year, 2 years and 3 years following the index procedure. The study was approved by an

16 institutional review board and/or ethical committee at each center participating in the study. All

17 enrolled patients provided informed written consent.

18 The objectives of the present study were to (i) determine the average daily ischemic rate

19 (ADIR) and average daily bleeding rate (ADBR) within different time intervals and overall

20 within the first year following primary PCI for STEMI (the time period for which aspirin and

21 clopidogrel were prescribed for all patients); (ii) to examine the extent to which recurrent events

22 contribute to the total burden of adverse outcomes; and (iii) to determine whether randomized

1   intraprocedural antithrombotic treatment (bivalirudin monotherapy versus UFH plus GPI)

2   affected these relative and absolute rates.

3   **Endpoint and Time Interval Definitions.** ADIR events were defined as cardiac death,

4   myocardial infarction (MI) and definite stent thrombosis (ST). ADBR events were defined as

5   Thrombolysis In Myocardial Infarction (TIMI) major and minor bleeding unrelated to coronary

6   artery bypass graft surgery (CABG). The definition of MI in the peri-procedural and non-

7   procedural periods has been previously described (9,10). ST was defined according to the

8   Academic Research Consortium criteria (13). Net adverse clinical events (NACE) were defined

9   as death, MI, definite ST and TIMI major and minor bleeding. The ADR for ischemic and

10   bleeding events were categorized according to the timing of their occurrence in the following

11   time intervals: acute phase ($\leq$24 hours), subacute phase (day 1 to day 30), early phase (0 to 30

12   days), and late phase (day 30 to day 365). To account for the sometimes delayed recognition and

13   diagnosis of bleeding events, ADRs were also examined using an alternative cut-off between the

14   acute and the subacute phases, specifically: day 0 to day 3 (modified acute phase) and day 3 to

15   day 30 (modified subacute phase). A clinical events committee blinded to treatment group

16   allocation independently adjudicated all endpoint events through original source documents

17   evaluation.

18   **Statistical Analyses.** The events of death (all-cause, cardiac and non-cardiac), MI,

19   definite ST, and TIMI major and minor bleeding unrelated to CABG were examined in all 3,602

20   patients randomized to bivalirudin monotherapy versus UFH plus GPI. For this analysis, all

21   events per patient were tabulated, as opposed to only the first event per patient, as is typically

22   reported in time-to-first-event analyses. For example, a single patient could have 1 ST, 2 MIs and

23   2 bleeds during the follow-up period. However, these had to be discrete, unrelated events. For

1   example, if a ST directly resulted in an MI, this was coded as only as a single ischemic event in

2   the composite ADIR endpoint. However, if an ischemic event led to a bleeding event (or vice-

3   versa), these were considered as two separate discrete events (i.e. a major bleed led to

4   development of an MI, or a ST led to a PCI with subsequent periprocedural major bleeding).

5   The ADR for a given interval was defined as the total number of events in that interval

6   divided by the total number of patient-days of follow-up (number of patients multiplied by how

7   many days each patient was at risk in that given period). Generalized estimating equations were

8   used to test the least square mean differences (LSMD) between the acute, subacute and late time

9   periods, with the patient as a repeated measure and assuming a Poisson distribution. The latter

10 analysis compared the average rates per patient and produced the LSMD, 95% confidence

11 intervals (CI) and p-values for the pairwise comparisons. Generalized estimating equations were

12 also used to test the LSMD between the average rates for ischemia and bleeding within each

13 specific interval. Because the definition of ABDR does not contain non-cardiac death, as a

14 sensitivity analysis we also calculated the LSMD between ischemia and bleeding after exclusion

15 of cardiac death from the composite AIDR endpoint (i.e. with AIDR comprised only of MI or

16 definite ST). For descriptive purposes, instantaneous daily rates, calculated as the number of

17 events on a given day divided by the number of patients at risk on that day (censoring only

18 deaths and patients lost to follow-up), were also determined - i.e. if on day 15 after PCI, 4 MIs

19 occurred out of 300 patients alive and at risk on that day, the instantaneous daily rate would be

20 1.3% (4/300). All analyses were then repeated in the randomized groups to determine the impact

21 of procedural antithrombotic treatment with bivalirudin vs. UFH plus GPI on the ADRs in

22 different time intervals, according to the intention-to-treat principle All statistical tests were 2-

sided. A P value below 0.05 was considered statistically significant for hypothesis testing.

Statistical analyses were performed with SAS version 9.4 (SAS Institute, Cary, North Carolina).

RESULTS

Among the 3,602 patients presenting with STEMI within 12 hours of symptom onset enrolled in HORIZONS-AMI, 279 discrete ischemic events (cardiac death, MI and definite ST) and 271 non-CABG-related TIMI major and minor bleeding events occurred within the first year following primary PCI for STEMI. Of these, 59/279 (21.1%) ischemic events and 43/271 (15.9%) bleeding events were recurrent and unrelated (Table 1). Conversely, most ischemic and bleeding events were not temporally related (Table 2). Only 22 of the 279 ischemic events (7.9%) were followed by a bleeding event, all occurring within 30 days. Following the 271 bleeding events, an ischemic event occurred in only 43 cases (15.9%), most 30/43 (69.8%) within 30 days.

The proportion of ischemic and bleeding events occurring in the acute, subacute and late time intervals is illustrated in Figure 1. Most of the bleeding events (90.8%) occurred in the early phase. Conversely, only 59.5% of ischemic events occurred within 30 days, while 40.5% of ischemic events occurred between 30 days and 1 year. The absolute number of ischemic and bleeding events occurring each day over the 1-year follow-up period is shown in Supplemental Figure 1, demonstrating the rapid and exponential reduction in the ADR of both ischemic and bleeding events after PCI in STEMI.

Average Daily Ischemic and Bleeding Rates Within 1 Year. The ADIR and ADBR up to 30 days, after 30 days and within the entire first year are shown in Figure 2. The ADIR peaked in the first 24 hours, and the ADBR peaked between day 2 and 3 (Supplemental Table 1). The

1   ADIR and ADBR in the acute, subacute, early and late phases are shown in Figure 3, Table 3,

2   Supplemental Table 2 (using the 3-day modified acute and subacute definitions) and in

3   Supplemental Table 3 (examining the in-hospital and out-of-hospital periods). Highly significant

4   reductions in both ADIR (Table 4 and Figure 3A) and ADBR (Table 4 and Figure 3B) were

5   observed as the patients transitioned from the acute to the subacute to the late periods (p<0.0001

6   for both ADIR and ADBR, across all time intervals). Results were consistent in the modified

7   acute and subacute intervals (Supplemental Table 4). The daily rates for ischemic and bleeding

8   events are shown in Supplemental Figure 2.

9   **Differences Between Average Daily Ischemic and Bleeding Rates at 1 Year.** LSMDs

10   between ADIR and ADBR across time intervals are shown in the **Central Illustration**. ADBR

11   significantly exceeded ADIR in the early phase (day 0 to 30 days; LSMD: -0.39%; 95% CI: -

12   0.58% to -0.20%; p<0.0001). Within the early phase, there was no significant difference between

13   ADIR and ADBR in the acute (0 to 1 day) phase, whereas ADBR exceeded ADIR in the

14   subacute (day 1 to 30) phase. Using the alternative 3-day cut-off (Supplemental Figure 3),

15   ADBR exceeded ADIR in the acute (day 0 to 3) phase, with no significant differences between

16   ADIR and ADBR in the subacute (day 3 to 30) phase. Finally, ADIR significantly exceeded

17   ADBR in the late phase (30 days to 1 year; LSMD: 1.51%; 95% CI: 1.04% to 1.98%; p<0.0001).

18   Results were consistent after excluding cardiac death from the composite ischemic endpoint

19   (Supplemental Figure 4).

20   **Average Daily Ischemic and Bleeding Rates According to the Antithrombotic**

21   **Treatment.** Differences in ADRs between bivalirudin-treated and UFH+GPI-treated patients are

22   illustrated in Supplemental Table 5 (using a cut-off of ≤24 hours for the acute phase) and

23   Supplemental Table 6 (using a cut-off of ≤3 days for the acute phase). At 30 days, bivalirudin

1 was associated with lower rates of bleeding and mortality, with no significant differences

2 observed in ADIR. Conversely, there were no significant differences in ADIR and ADBR

3 between the two groups beyond 30 days. LSMDs between ADIR and ADBR in the bivalirudin

4 arm and the UFH + GPI arm are shown in Supplemental Figure 5 and Supplemental Figure 6,

5 respectively. In patients treated with bivalirudin, there were no significant differences between

6 ADIR and ADBR within the first 30 days, whereas in patients treated with UFH + GPI, the rates

7 of ADBR exceeded the rates of ADIR in the early period. ADIR significantly exceeded ADBR in

8 the late phase (30 days to 1 year) for both antithrombotic regimens.

9

10 **DISCUSSION**

11   The main findings from the present analysis, in which the absolute and relative daily and

12 interval rates of ischemic and bleeding events were characterized in the first year after primary

13 PCI in 3,602 STEMI patients maintained on a dual antiplatelet regimen of aspirin and

14 clopidogrel, are as follows: (i) the ADRs for both ischemic and bleeding events, including

15 recurrent events, were highest early after the procedure and then rapidly declined over time; (ii)

16 in the early period (0-30 days), the absolute rates of bleeding exceeded those of ischemia, and

17 were influenced by the type of intraprocedural anticoagulation; (iii) in the late period (30 days to

18 1 year), the ADR of ischemic events exceeded that of bleeding; in this period the rates of

19 ischemia and bleeding were unaffected by the procedural anticoagulation regimen. These novel

20 findings elucidate the time-related differences in the offsetting rates of ischemia and bleeding

21 after primary PCI, and have implications for the use of more potent P2Y12 inhibitors and other

22 bleeding avoidance strategies during various intervals after mechanical reperfusion therapy in

23 STEMI.

13

1   The current analysis from the HORIZONS-AMI trial extends the findings from prior

2   studies in which the competing daily rates of ischemia and bleeding have been examined.

3   Previously, Bhatt et al in a post-hoc analysis from the Clopidogrel for High Atherothrombotic

4   Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial estimated the

5   daily instantaneous hazard of ischemic and bleeding events at 3 years in stable patients on aspirin

6   plus placebo or clopidogrel.(14) However, conventional time-to-event analyses (such as Kaplan-

7   Meier methods and Cox proportional hazard models) are limited by the fact that patients are

8   censored after the occurrence of the first endpoint event. This approach does not allow

9   evaluation of multiple or recurrent events over time, and therefore impedes full appreciation of

10   the overall disease burden and effects of concomitant treatments (15). For example, in trials of

11   heart failure therapies, as many as 50% of heart failure re-hospitalizations are recurrent events

12   occurring in single participants (16,17). Application of time-to-first-event analysis for such

13   endpoints results in a substantial loss of information and statistical power (18). In the present

14   study, we examined the daily risk of discrete first time and recurrent ischemic and bleeding

15   events over 1 year after primary PCI for STEMI. Approximately 21% of all ischemic events and

16   16% of all bleeding events occurring within 1 year were recurrent events. Moreover, by detailed

17   chart review we examined the inter-relationship of ischemic and bleeding events. For example, it

18   might be envisioned that many major bleeds during follow-up arise from PCI treatment of

19   ischemic complications (e.g. ST), or that many ischemic events arise after discontinuation of

20   anti-platelet agents or other therapies to treat major bleeding. However, in contrast to this

21   expectation, only a small proportion of adverse ischemic and bleeding events were temporally

22   related to bleeding and ischemic events, respectively. These findings place into perspective the

23   total burden of adverse events that occur within the first year after primary PCI for STEMI (in

patients treated with a dual antiplatelet regimen of aspirin and clopidogrel), and emphasize the

relative independence of ischemic and bleeding complications in these high-risk patients.

The absolute risk for ischemic events was highest early after the PCI procedure, and then

exponentially decayed over time. This finding emphasizes that the early period (especially the

first few days after primary PCI) is the interval in which more potent anti-platelet agents may

have the greatest utility in improving prognosis. However, the absolute rate of bleeding was also

greatest in this early period, and as such more potent agents may also produce harm in this

interval. Such a trade-off is evidenced by procedural anticoagulation with bivalirudin rather than

UFH + GPI, which in the first 24 hours results in greater rates of ST but less major bleeding.

These offsetting risks can be favorably affected by routine use of a post-procedural bivalirudin

infusion at 1.75 mg/kg/hr for 3-4 hours post-PCI, which may eliminate the excess acute risk of

ST without increasing bleeding (19-21). Similarly, intensification of $P2Y_{12}$ receptor inhibition

with intravenous cangrelor compared to clopidogrel during the PCI procedure and for the first 2-

4 hours thereafter favorably reduces the acute and 48-hour rates of MI and ST without increasing

major bleeding (22). In contrast, while use of prasugrel rather than clopidogrel in patients with

acute coronary syndromes (ACS) was highly effective in reducing adverse ischemic events early

after PCI, the excessive bleeding complications with this irreversible agent (including an

increase in fatal and life-threatening bleeding) offset much of its benefits (23). Finally, given that

in the first 30 days the overall burden of bleeding exceeded that of ischemia, bleeding avoidance

strategies in this early high-risk period may be particularly effective in favorably shifting the

benefit-risk equation. This finding possibly explains the early survival benefit seen in patients

with STEMI undergoing primary PCI with radial artery compared to femoral artery access, and

1   with bivalirudin compared to UFH with or without GPI as intraprocedural antithrombotic therapy

2   (24,25).

3   In contrast to the first 30 days, ischemic and bleeding rates were substantially lower after

4   30 days, and unaffected by the procedural anticoagulation regimen. However, in this period the

5   absolute rate of ischemia was ~1.5% greater than the absolute rate of bleeding (representing a

6   relative increase of ~50-fold) **(Central Illustration)**, suggesting a particularly beneficial role in

7   the late period for an agent able to further reduce ischemia (as long as major bleeding is not

8   markedly increased). This finding may underlie the findings from the Study of Platelet Inhibition

9   and Patient Outcomes (PLATO) trial, in which patients with STEMI and non-STEMI treated

10 with aspirin plus ticagrelor rather than aspirin plus clopidogrel experienced a 1-year reduction in

11 the rates of MI, ST, cardiac mortality and non-cardiac mortality, despite a modest increase in

12 non-CABG-related major bleeding (26). Of note, the benefits of ticagrelor in this trial did not

13 begin to emerge until several weeks after initiation, and continued to diverge throughout the 1-

14 year follow-up period, as predicted from the present study (26). Thus, the current analysis

15 confirms current guidelines supporting consistent and high-intensity platelet inhibition to at least

16 1 year after primary PCI in STEMI, emphasizing the selection of agents and consideration of

17 patient co-morbidities to ensure an optimal balance of ischemia suppression and bleeding risk

18 (27).

19   The insights from the present study may also have bearing on the design of future

20 randomized controlled trials for primary or secondary prevention in patients with ACS and in

21 those undergoing PCI. In particular, inclusion of recurrent events (i.e. reinfarction or re-

22 hospitalization for cardiac causes) as a pre-specified primary outcome measure may increase the

23 number of endpoint events facilitating studies of smaller sample size (impacting trial feasibility)

or with greater power (10). Such an approach may also allow for a more accurate estimation of the impact of a given intervention on overall disease burden. However, the present study also underscores the time dependence of the absolute and relative risks of off-setting events in disease states, as well as the potential risks vs. benefits of applying different therapeutic approaches in different periods. A treatment that offers a favorable benefit-risk profile early after patient presentation may not provide net clinical benefit later on (or vice versa).

Limitations. The implications of our study findings should be assessed considering its strengths, limitations and unknowns. This analysis was performed from a large, prospective, international, multicenter randomized controlled trial with complete monitoring and event adjudication, therefore providing robust findings. Only first-generation drug-eluting stents and bare metal stents were used, and we did not study an UFH only arm, which some centers employ in primary PCI. In addition, more than 90% of patients were treated via femoral access, which has been associated with greater risk of bleeding and vascular complications than transradial access (24,25). However, in contemporary US practice, femoral access and UFH+GPI are still used in up to 90% and 40% of STEMI cases, respectively (28). Novel and more potent $P2Y_{12}$-receptor inhibitors (ticagrelor, prasugrel and cangrelor) were not available during study enrollment, and therefore our findings apply to an aspirin and clopidogrel-treated population. These newer treatments may affect the absolute and relative risks of ischemia vs. bleeding, although the general concepts still apply. Moreover, clopidogrel is still prescribed at hospital discharge in up to 60-70% of patients with acute coronary syndromes in the United States (29-31). The net effects of new strategies capable of suppressing ischemia but which may also increase bleeding depend on: 1) the absolute rates of these competing risks; 2) the relative reduction in ischemia vs. increase in bleeding with the new therapy; and 3) the relative impact of

ischemia vs. bleeding on overall patient outcomes, for example as measured by their effect on mortality, a factor not considered in the present report but previously investigated in both acute (32) and more chronic settings (33). In this regard, in the HORIZONS-AMI trial, non-CABG-related protocol-defined bleeding was at least as strongly associated with all-cause mortality through 3-year follow-up as was reinfarction (adjusted HR 3.44 vs 2.88 respectively) (33). The observed peak for the rate of bleeding between day 2 and 3 may be related to ascertainment bias due to the typical nadir in hemoglobin that occurs after a periprocedural hemorrhagic event. For this reason we presented a sensitivity analysis with acute events defined as those occurring within 3 days. Finally, in the current analysis we estimated ADRs in the overall trial population. Since the absolute rates of ischemia and bleeding may vary with individual patient risk factors, further analyses are warranted to identify subgroups at relatively higher or lower risk for recurrent ischemic vs. bleeding events who may differentially benefit from more intensive anti-ischemic therapies or bleeding avoidance approaches, respectively.

Conclusions. In the HORIZONS-AMI trial, in patients with STEMI treated with primary PCI on a background of aspirin and clopidogrel for 1 year, the daily risk for both adverse ischemic and bleeding events was highest early after the procedure and then dramatically declined over time. However, in contrast to the early period, beyond 30 days the absolute risk for ischemia exceeded the risk for bleeding. The current findings support the use of potent platelet inhibition continuing through at least 1 year to prevent both primary and recurrent ischemic events, especially in patients without excessive bleeding risk. Implementation of bleeding avoidance strategies is also essential, especially in the acute and subacute phases after primary PCI. Finally, a substantial proportion of both ischemic and bleeding events that occurred during the 1 year follow-up period were discrete, recurrent events, although in most cases not related to

each other – these considerations should be taken into account when evaluating the effect of pharmacotherapies for secondary prevention after STEMI.

REFERENCES

1. Mehran R, Pocock S, Nikolsky E et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc Interv 2011;4:654-64.

2. van Werkum JW, Heestermans AA, Zomer AC et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009;53:1399-409.

3. Genereux P, Giustino G, Witzenbichler B et al. Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. Journal of the American College of Cardiology 2015;66:1036-45.

4. Giustino G, Baber U, Stefanini GG et al. Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol 2015;116:845-52.

5. Gutierrez A, Bhatt DL. Balancing the risks of stent thrombosis and major bleeding during primary percutaneous coronary intervention. Eur Heart J 2014;35:2448-51.

6. Giustino G, Baber U, Sartori S et al. Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol 2015.

7. Giustino G, Chieffo A, Palmerini T et al. Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. J Am Coll Cardiol 2016;68:1851-1864.

8. Steg PG, James S, Harrington RA et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous

coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010;122:2131-41.

9. Montalescot G, Wiviott SD, Braunwald E et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723-31.

10. Pocock SJ, Stone GW. The Primary Outcome Fails - What Next? N Engl J Med 2016;375:861-70.

11. Stone GW, Witzenbichler B, Guagliumi G et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30.

12. Stone GW, Lansky AJ, Pocock SJ et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009;360:1946-59.

13. Cutlip DE, Windecker S, Mehran R et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.

14. Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology 2007;49:1982-8.

15. Amorim LD, Cai J. Modelling recurrent events: a tutorial for analysis in epidemiology. Int J Epidemiol 2015;44:324-33.

16. Rogers JK, Jhund PS, Perez AC et al. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Fail 2014;2:289-97.

17. Rogers JK, Pocock SJ, McMurray JJ et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Fail 2014;16:33-40.

18. Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61.

19. Valgimigli M, Frigoli E, Leonardi S et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med 2015;373:997-1009.

1   20.   Han Y, Guo J, Zheng Y et al. Bivalirudin vs heparin with or without tirofiban during

2   primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT

3   randomized clinical trial. JAMA 2015;313:1336-46.

4   21.   Clemmensen P, Wiberg S, Van't Hof A et al. Acute stent thrombosis after primary

5   percutaneous coronary intervention: insights from the EUROMAX trial (European

6   Ambulance Acute Coronary Syndrome Angiography). JACC Cardiovasc Interv

7   2015;8:214-20.

8   22.   Bhatt DL, Stone GW, Mahaffey KW et al. Effect of platelet inhibition with cangrelor

9   during PCI on ischemic events. N Engl J Med 2013;368:1303-13.

10   23.   Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients

11   with acute coronary syndromes. N Engl J Med 2007;357:2001-15.

12   24.   Leonardi S, Frigoli E, Rothenbuhler M et al. Bivalirudin or unfractionated heparin in

13   patients with acute coronary syndromes managed invasively with and without ST

14   elevation (MATRIX): randomised controlled trial. BMJ 2016;354:i4935.

15   25.   Del Furia F, Giustino G, Chieffo A. Targeting transradial approach: an updated

16   systematic review and meta-analysis. Panminerva Med 2016;58:329-340.

17   26.   Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with

18   acute coronary syndromes. N Engl J Med 2009;361:1045-57.

19   27.   Levine GN, Bates ER, Bittl JA et al. 2016 ACC/AHA Guideline Focused Update on

20   Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A

21   Report of the American College of Cardiology/American Heart Association Task Force

22   on Clinical Practice Guidelines. J Am Coll Cardiol 2016;68:1082-115.

23   28.   Secemsky EA, Kirtane A, Bangalore S et al. Use and Effectiveness of Bivalirudin Versus

24   Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With

25   ST-Segment Elevation Myocardial Infarction in the United States. JACC Cardiovasc

26   Interv 2016;9:2376-2386.

27   29.   Baber U, Sartori S, Aquino M et al. Use of prasugrel vs clopidogrel and outcomes in

28   patients with acute coronary syndrome undergoing percutaneous coronary intervention in

29   contemporary clinical practice: Results from the PROMETHEUS study. Am Heart J

30   2017;188:73-81.

30. Fosbol EL, Ju C, Anstrom KJ et al. Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome). Circ Cardiovasc Interv 2016;9.

31. Bradley SM, Hess GP, Stewart P et al. Implications of the PEGASUS-TIMI 54 trial for US clinical practice. Open Heart 2017;4:e000580.

32. Chew DP, Bhatt DL, Lincoff AM, Wolski K, Topol EJ. Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk. Heart 2006;92:945-50.

33. Stone SG, Serrao GW, Mehran R et al. Incidence, predictors, and implications of reinfarction after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial. Circ Cardiovasc Interv 2014;7:543-51.

22

PERSPECTIVES

Competency in Medical Knowledge: After primary PCI for STEMI the risk of first and recurrent ischemic and bleeding events is highest early after the procedure to then drastically decline over time. While the rates for bleeding exceeded those for ischemic events within 30 days, the risk for ischemia significantly exceeded the risk for bleeding beyond 30 days.

Competency in Patient Care: The present analysis supports the use of intensified platelet inhibition from clinical presentation throughout the first year after STEMI. Physicians should take into account the time-dependent and off-setting risk of recurrent ischemic and bleeding events when tailoring duration and potency of antiplatelet therapies.

Translational Outlook: Future randomized controlled trials in the field of acute coronary syndromes should be designed to evaluate the overall burden of events by considering recurrent adverse events, which are censored in conventional time-to-event analyses.

Figure Legends

2 **Figure 1. Adverse event proportions during the first year after primary PCI for STEMI.**

3 Panel A: Proportion of adverse events occurring in the acute (≤24 hours), subacute (day 1 to day

4 30), and late (day 30 to day 365) periods; Panel B: Proportion of adverse events occurring in the

5 early (day 0 to day 30) and late (day 30 to day 365) periods. ADIR = Average Daily Ischemic

6 Rate; ADBR = Average Daily Bleeding Rate; NACE = Net Adverse Clinical Events.

7

8 **Figure 2. Average daily ischemic and bleeding rates within 1 year after primary PCI for**

9 **STEMI.** Panel A: From day 0 to day 365; Panel B: From day 0 to day 30. Panel C: From day 30

10 to day 365. ADIR = Average Daily Ischemic Rate; ADBR = Average Daily Bleeding Rate; PCI:

11 Percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction.

12

13 **Figure 3**. **Reductions in average daily ischemic and bleeding rates from the acute to the**

14 **subacute to the late periods after primary PCI for STEMI.** Panel A: Ischemic rate; Panel B:

15 Bleeding rate. LSMD: Least Square Mean Differences.

16

17 **Central Illustration. Temporal differences in ischemic and bleeding rates after primary**

18 **PCI for STEMI.** Least square mean differences (LSMD) between the average daily ischemic

19 and bleeding rates in the acute, subacute, early and late periods. The x-axis displays time. The y-

20 axis displays the LSMD between ischemia and bleeding, with LSMD >1 if ischemia exceeds

21 bleeding and LSMD <1 if bleeding exceeds ischemia. In the early period (before 30 days), the

22 rates of bleeding exceed those for ischemia. In the late period (from 30 days to 1 year), ADIR

1   significantly exceeds ADBR. ADBR: Average Daily Bleeding Rate; ADIR: Average Daily

2   Ischemic Rate; CI: confidence interval; LSMD: least square mean differences.

Table 1. Number of patients with discrete events within each time period and during the total 1-year study period

Endpoint	Acute (day 0 to day 1)	Subacute (day 1 to day 30)	Late (day 30 to day 365)	Overall (day 0 to day 365)
Cardiac death, reinfarction or definite stent thrombosis				
Total events	37	129	113	279
Patients with 1 event	37	106	83	220
Patients with 2 events	-	10	10	21
Patients with 3 events	-	1	2	3
Patients with 4 events	-	-	1	2
Death				
Total events	20	73	54	147
Patients with 1 event	20	73	54	147
Non-cardiac death				
Total events	1	8	33	42
Patients with 1 event	1	8	33	42
Cardiac death				
Total events	19	65	21	105
Patients with 1 event	19	65	21	105
Reinfarction				
Total events	14	58	85	157
Patients with 1 event	14	47	70	127
Patients with 2 events	-	4	4	7
Patients with 3 events	-	1	1	4
Patients with 4 events	-	-	1	1
Definite stent thrombosis				
Total events	21	47	32	100
Patients with 1 event	21	37	26	82
Patients with 2 events	-	5	3	6
Patients with 3 events	-	-	-	2
TIMI major and minor				

bleeding

Total events	33	213	25	271
Patients with 1 event	33	197	22	228
Patients with 2 events	-	5	-	17
Patients with 3 events	-	2	1	3

TIMI: Thrombolysis In Myocardial Infarction.

Table 2. Relationships between ischemic and bleeding events

Primary event	Secondary event	0 to 7 days	7 to 30 days	0 to 30 days	30 days to 1 year	0 to 1 year
Bleeding (N=271)	Ischemia (N=43)	20/271 (7.4%)	10/271 (3.7%)	30/271 (11.1%)	13/271 (4.8%)	43/271 (15.9%)
	- MI or ST (N=18)	5/271 (1.8%)	4/271 (1.5%)	9/271 (3.3%)	9/271 (3.3%)	18/271 (6.6%)
	- Cardiac death (N=25)	15/271 (4.8%)	6/271 (2.2%)	21/271 (7.0%)	4/271 (1.5%)	25/271 (9.2%)
Ischemia (N=279)	Bleeding (N=22)	13/279 (4.7%)	9/279 (3.2%)	22/279 (7.9%)	0/279 (0.0%)	22/279 (7.9%)

Results represent number of recurrent events / number of primary bleeding or ischemic events (%). Proportion of ischemic and bleeding events occurring within 365 days following a bleeding (upper panel) or ischemic event (lower panel), respectively. MI: Myocardial infarction; ST: Stent thrombosis.

Table 3. Average daily rates for adverse events in the acute, subacute, early and late periods

Endpoint	Acute (≤24 hours)	Subacute (day 1 to day 30)	Early (day 0 to day 30)	Late (day 31 to day 365)
Average daily ischemic rate*	37/3602 (1.0272%)	129/105435 (0.1224%)	166/109037 (0.1522%)	113/1116866 (0.0101%)
Cardiac death	19/3602 (0.5275%)	65/105435 (0.0616%)	84/109037 (0.0770%)	21/1116866 (0.0019%)
Reinfarction	14/3602 (0.3887%)	58/105435 (0.0550%)	72/109037 (0.0660%)	85/1116866 (0.0076%)
Definite stent thrombosis	21/3602 (0.5830%)	47/105435 (0.0446%)	68/109037 (0.0624%)	32/1116866 (0.0029%)
Average daily bleeding rate†	33/3602 (0.9162%)	213/105435 (0.2020%)	246/109037 (0.2256%)	25/1116866 (0.0022%)
Average daily mortality rate	20/3602 (0.5552%)	73/105435 (0.0692%)	93 /109037 (0.0853%)	54/1116866 (0.0048%)
Non-cardiac death	1/3602 (0.0278%)	8/105435 (0.0076%)	9/109037 (0.0083%)	33/1116866 (0.0030%)
Average daily net adverse clinical events rate‡	70/3602 (1.9434%)	342/105435 (0.3244%)	412/109037 (0.3779%)	138/1116866 (0.0124%)

Data reported as number of events/patient-day of follow-up (average daily rate) in each time-period. *Defined as cardiac death, reinfarction and definite stent thrombosis. †Defined as non-CABG-related TIMI major and minor bleeding. ‡Defined as any death, reinfarction, definite stent thrombosis, and non-CABG-related TIMI major and minor bleeding.

Table 4. Differences in average daily rates for adverse events in the acute, subacute, early and late periods.

	Acute vs. Subacute Period			Acute vs. Late Period		
	Difference	95% CI	P-value	Difference	95% CI	P-value
Average daily ischemic rate	2.13%	1.75 - 2.50	<0.0001	4.62%	4.24 - 5.00	<0.0001
Cardiac death	2.15%	1.64 - 2.66	<0.0001	5.64%	5.02-6.26	<0.0001
Reinfarction	1.96%	1.36 - 2.55	<0.0001	3.93%	3.37-4.50	<0.0001
Definite stent thrombosis	2.57%	2.04 - 3.10	<0.0001	5.32%	4.77-5.87	<0.0001
Average daily bleeding rate	1.51%	1.15 - 1.87	<0.0001	6.01%	5.48 - 6.55	<0.0001
Average daily mortality rate	2.08%	1.59 - 2.58	<0.0001	4.74%	4.23 - 5.26	<0.0001
Non-cardiac death	1.30%	-0.78 - 3.38	0.22	2.24%	0.25 - 4.23	0.03
Average daily net adverse clinical events rate	1.79%	1.54 - 2.04	<0.0001	5.06%	4.76 - 5.35	<0.0001

	Subacute vs. Late Period			Early vs. Late Period		
	Difference	95% CI	P-value	Difference	95% CI	P-value
Average daily ischemic rate	2.49%	2.21 - 2.78	<0.0001	2.71	2.44 - 2.98	<0.0001
Cardiac death	3.49%	3.00 - 3.98	<0.0001	3.71	3.23 - 4.19	<0.0001
Reinfarction	1.98%	1.61 - 2.35	<0.0001	2.16	1.82 - 2.50	<0.0001
Definite stent thrombosis	2.74%	2.26 - 3.23	<0.0001	3.08	2.64 - 3.52	<0.0001
Average daily bleeding rate	4.50%	4.05 - 4.95	<0.0001	4.62	4.18 - 5.07	<0.0001
Average daily mortality rate	2.66%	2.31 - 3.01	<0.0001	2.87	2.53 - 3.21	<0.0001
Non-cardiac death	0.94%	0.17 - 1.72	0.02	1.03	0.29 - 1.76	0.006

Average daily net adverse clinical events rate	3.27%	3.04 - 3.50	<0.0001	3.42	3.20 - 3.64	<0.0001

Least square mean differences, confidence intervals and p-values for pairwise comparisons between the patient-day event rates across the acute (day 0 to day 1), subacute (day 1 to day 30) and late (day 30 to day 365) periods. Generalized estimating equations were used to test the rate for differences between the three time periods with the patient as a repeated measure and assuming a Poisson distribution. Differences in reinfarction are not estimable due to absence of events in the acute phase. CI: confidence interval.